Find Venous Thromboembolism (VTE) Clinical Trials Near You
External Validation of a Predictive Model for Occult Cancer Risk in Patients With Venous Thromboembolism Developed Using Machine Learning
Status: Recruiting
Location: See all (12) locations...
Study Type: Observational
SUMMARY
This study aims to externally validate the CLOVER score, a machine learning-based predictive model designed to identify patients with venous thromboembolism (VTE) who are at increased risk of having an occult cancer. The study includes a retrospective cohort of patients with acute symptomatic VTE diagnosed between 2000 and 2022, and a prospective cohort of consecutively recruited patients from December 2025 to December 2027. The CLOVER model will be applied to all participants, and its ability to discriminate between patients with and without occult cancer will be evaluated. The study also assesses clinicians' satisfaction with the web-based tool (CLOVER-Web) developed to facilitate the use of the score in clinical practice.
• Ability to provide written or electronic informed consent.
Locations
Other Locations
Spain
Hospital San Agustín
RECRUITING
Avilés
Hospital Universitario Son Llatzer
RECRUITING
Balea
Hospital Clínic
RECRUITING
Barcelona
Hospital Universitario 12 de Octubre
RECRUITING
Madrid
Hospital Universitario de Fuenlabrada
RECRUITING
Madrid
Hospital Universitario de Móstoles
RECRUITING
Madrid
Hospital Universitario Infanta Leonor
RECRUITING
Madrid
Hospital Universitario La Paz
RECRUITING
Madrid
Hospital Universitario Príncipe de Asturias
RECRUITING
Madrid
Hospital Universitatio del Sureste
RECRUITING
Madrid
Hospital Clínico Universitario Virgen de la Arrixaca
RECRUITING
Murcia
Hospital Universitario Morales Meseguer
RECRUITING
Murcia
Contact Information
Primary
Anabel Franco Moreno, MD, PhD
afranco278@hotmail.com
+34686102661
Backup
Anabel Franco Moreno
afranco278@hotmail.com
MD, PhD
Time Frame
Start Date:2025-12-01
Estimated Completion Date:2028-12-31
Participants
Target number of participants:500
Treatments
Prospective VTE Cohort
Adults with objectively confirmed symptomatic venous thromboembolism (deep vein thrombosis and/or pulmonary embolism) consecutively enrolled from December 2025 to December 2027 in participating hospitals. All participants will undergo routine clinical evaluation, laboratory testing, and cancer screening according to standard practice. The CLOVER score will be calculated at baseline using the web-based tool (CLOVER-Web).